317-34-0

Usage

InChI:InChI=1/2C7H8N4O2.C2H8N2.H2O/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4;/h2*3H,1-2H3,(H,8,9);1-4H2;1H2

Synthetic route

theophylline (58-55-9) + ethylenediamine (107-15-3) → theophylline ethylenediamine (317-34-0)

Conditions	Yield
In methanol; ethyl acetate at 5 - 80℃; for 2.5h; Temperature;	91.8%

sodium 1,2-naphthoquinone-4-sulfonate (521-24-4) + theophylline ethylenediamine (317-34-0) → 2C7H8N4O2*C22H20N2O4

Conditions	Yield
In sodium hydroxide at 40℃; pH=13.00; Kinetics; Further Variations:; Temperatures;

Upstream product

• 107-15-3 ethylenediamine 
• 58-55-9 Theophylline 
• 58-55-9 theophylline 

Downstream Products

• 107-15-3 ethylenediamine 
• 58-55-9 Theophylline 

Relevant academic research and scientific papers

11/2 aminophylline hydrate compound

The invention provides a 11/2 aminophylline hydrate compound and a preparation method thereof, wherein the compound is determined by a powder X-ray diffraction determination method, and characteristicdiffraction peaks are shown at 10.8 degrees, 12.0 degre

LIQUID PHARMACEUTICAL FOR ORAL DELIVERY

A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.